Is STE a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for STERIS plc (STE) rests on Recurring consumables and service, not equipment sales: Most of what STERIS books each quarter is not a machine. The bear case rests on ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Analysts covering it publish targets from $244.00 to $305.00 against a $255.76 share price on November 20, 2026, so even the professionals disagree by 22% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

STE key stats

At $255.76 on November 20, 2026, STERIS plc (STE) has a market cap of $24.8B, a P/E of 30.3 on trailing earnings (20.5 on forward earnings) and a dividend yield of 1.08%. It next reports earnings around February 3, 2027 (estimated).

Market cap
$24.8B
P/E (trailing)
30.3
P/E (forward)
20.5
EPS (trailing 12 months)
$8.43
Price to book
3.4
Dividend yield
1.08%
Beta
0.86
Next earnings
around February 3, 2027 (estimated)

Market cap, P/E and yield are measured at the $255.76 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with STERIS plc (STE)?

The last two weeks for STERIS plc, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • STE closed at $255.76 on November 20, 2026, down 3.2% over the past five trading days (from $264.32).
  • STERIS plc next reports quarterly results around February 3, 2027 (estimated).
  • On November 12, 2026, STERIS plc filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov
  • On November 13, 2026, Jefferies raised its target to $305.00 from $232.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

STERIS plc makes the equipment, chemistries and services that keep hospital operating rooms and medical device production sterile. Three segments carry the business. Healthcare, roughly ~70% of revenue, sells sterilizers, washers, surgical tables, endoscopy reprocessing systems and the consumables and service contracts that follow them into hospitals. Applied Sterilization Technologies (AST), close to ~20% of revenue, runs contract sterilization facilities that gamma-irradiate, e-beam or ethylene oxide treat devices for manufacturers before those devices ship. Life Sciences, near ~10%, supplies cleaning chemistries, small sterilizers and validation services to pharmaceutical producers. Legally the parent is an Irish plc, operationally the company runs out of Mentor, Ohio, and the ordinary shares trade on the NYSE inside the S&P 500. Headcount is roughly ~17,900. The investment picture rests on installed base rather than on new orders. A sterilizer sold today drags decades of chemistries, filters, service visits and replacement parts behind it, which is why STERIS grew revenue ~9% in fiscal 2026 to ~$5.9 billion and guided fiscal 2027 to another ~7% to ~8%; in November it raised adjusted EPS guidance to ~$11.35 to ~$11.55 from ~$11.10 to ~$11.30. Trailing revenue now sits near ~$6.17 billion. Capital equipment is the cyclical part and moves with hospital budgets; AST moves with how many devices its customers actually manufacture, so a destocking cycle at a large device maker shows up in STERIS volumes with a lag. Cash generation is the quiet strength, with trailing free cash flow near ~$820 million against debt of roughly ~$2.05 billion, which funded the ~$600 million chemistries plant announced in North Carolina, a ~$1 billion buyback authorization and a dividend raised for a 21st consecutive year. The newest chapter is an acquisition. On October 12, 2026 STERIS signed a definitive agreement to buy Xodus Medical, a Pittsburgh-area maker of operating room consumables best known for its Pink Pad patient positioning systems, for ~$2.1 billion at closing (about ~$1.8 billion net of expected cash tax benefits) plus up to ~$150 million in an earnout tied to calendar 2028 targets. Xodus is projected at ~$245 million of calendar 2026 revenue with adjusted EBIT near ~$135 million. The deal is to be financed primarily with debt and is expected to close by December 31, 2026, after which STERIS plans to reissue its fiscal 2027 outlook. The fiscal second quarter (July through September 2026), reported in early November, brought revenue of ~$1.59 billion, up ~9% (~8% organic in constant currency), and adjusted EPS of ~$2.94 against a ~$2.68 consensus, up ~19% from a year earlier. Life Sciences grew ~18%, Healthcare ~7% and AST ~5%. Management raised fiscal 2027 adjusted EPS guidance to ~$11.35 to ~$11.55, a figure that includes ~$0.18 a share of tariff refunds received so far and excludes Xodus; revenue guidance of ~7% to ~8% was unchanged, with Life Sciences raised and AST trimmed to ~6% to ~7%. Jefferies upgraded the shares to Buy with a ~$305 target on November 13. The stock trades near ~$256 as of November 20, 2026, up ~2% year to date and roughly flat (~-0.4%) over the past year, after a ~10% gain over the last month.

The bull case: what would have to be true for $305.00

The most optimistic published target on STE is $305.00, +19.3% from the $255.76 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Recurring consumables and service, not equipment sales

Most of what STERIS books each quarter is not a machine. Consumables and service revenue attach to an installed base that hospitals cannot easily rip out, since sterilization workflows are validated, regulated and staff-trained around specific equipment. In the fiscal 2026 fourth quarter Healthcare service revenue grew ~9% and consumables ~7% while capital equipment grew ~6%, the pattern that lets reported growth hold up when hospital capital budgets tighten. The Xodus Medical deal pushes further in the same direction, adding a consumables line that is used case by case in the operating room.

2. Outsourced sterilization volume tied to device manufacturing

AST is effectively a toll road for the medical device industry: manufacturers send product through STERIS facilities because building and validating sterilization capacity in-house rarely pays. Segment revenue reached ~$297.6 million in the fiscal 2027 first quarter, up ~6%, and organic growth slowed to ~5% in the second quarter, so management trimmed its AST forecast for the year to ~6% to ~7%. Capacity is geographically sticky, so incremental volume drops through at high margins once a plant is running.

3. Reinvestment into chemistries and consolidated manufacturing

Management committed roughly ~$600 million to a Formulated Chemistries Center of Excellence in North Carolina, phased across fiscal 2028 and fiscal 2029, alongside a targeted restructuring plan that consolidates existing chemistry sites. Company targets point to better than a ~10% return on invested capital within three to five years. Execution risk is real, and the market reaction to the announcement was mixed because the spending lands before the savings do.

4. Balance sheet now put to work on Xodus Medical

Leverage was low for a healthcare industrial going into the autumn, with debt near ~$2.05 billion against ~$1.68 billion of EBITDA, and STERIS has historically used that room for acquisitions, Cantel Medical in 2021 being the largest. The ~$2.1 billion Xodus purchase, financed primarily with debt, roughly doubles that borrowing once it closes. STERIS says the deal should add to revenue growth, margins and adjusted earnings, but has not put a number on the accretion. The quarterly dividend stands at ~$0.69 per share, and the pace of buybacks under the ~$1 billion authorization is likely to slow while the new debt is paid down.

The bear case: what would have to be true for $244.00

The most pessimistic published target is $244.00, -4.6% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks STERIS plc is worth if the risks below bite instead of the drivers above.

Ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Subsidiary Isomedix agreed to costs of up to roughly ~$48 million to resolve personal injury claims tied to an Illinois sterilization plant, and EtO emissions rules adopted by the EPA in 2024 remain in flux under reconsideration, which cuts both ways: looser rules reduce compliance capex, while continued legal uncertainty has already caused the company to hold off on some capacity expansion. Hospital capital spending is the second pressure point, since sterilizers and surgical tables are deferrable purchases when health systems face margin strain. AST volumes depend on customer manufacturing schedules rather than on STERIS decisions, so device industry destocking passes straight through. The Xodus Medical acquisition adds deal risk: ~$2.1 billion for a business with ~$245 million of revenue is a rich price, the debt it adds raises leverage, and closing depends on regulatory approvals. Tariffs and currency both moved reported results in fiscal 2026 and management flagged them again in the fiscal 2027 outlook. Valuation is itself a risk, because a ~30x trailing multiple leaves little room for a guidance cut, and part of the November guidance raise came from one-off tariff refunds.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding STE already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on STE

7 analysts cover STE, with an average target of $281.14 (+9.9% against $255.76) and a split of 6 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the STE forecast and price target page.

How is STE valued?

Market cap, P/E and dividend yield at today's price are in the STE key stats above. The business figures below come from STERIS plc's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$6.17 billion, up ~9% year over year in the latest quarter
  • Margins: ~44% gross, ~19% operating, ~13% net
  • Net income (TTM): ~$827 million, trailing EPS of ~$8.43
  • Dividend: ~$0.69 per quarter, a yield near ~1.1%, raised for a 21st straight year
  • Debt and cash: ~$2.05 billion debt, ~$531 million cash, before the debt-funded Xodus deal

As of November 2026: STERIS runs a March fiscal year, so the trailing twelve months as of November 2026 spans the final two quarters of fiscal 2026 plus the June and September 2026 quarters of fiscal 2027. The September quarter brought revenue of ~$1.59 billion and adjusted EPS of ~$2.94 against a ~$2.68 consensus, and the shares have climbed back to ~30x trailing and ~22x this fiscal year's expected earnings. The mean target of seven analysts tracked by Yahoo Finance is near ~$281, the next report is expected around early February 2027, and the outlook will be reworked once the Xodus acquisition closes.

How do you decide if STE is a buy?

Whether STE is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold STE indirectly through an index or sector ETF before adding more.

What would change your mind on STE

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Recurring consumables and service, not equipment sales stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the STE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about STE against your real portfolio and see your actual exposure before deciding.

Your questions about STERIS plc

Ask Walnut's AI anything about STE and see how it fits what you own.

FAQ

Is STE a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Recurring consumables and service, not equipment sales, with revenue (ttm) at ~$6.17 billion, up ~9% year over year in the latest quarter. The bear case rests on ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Analysts covering it are spread from $244.00 to $305.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell STE?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $244.00, -4.6% from the $255.76 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for STE?

+

Recurring consumables and service, not equipment sales. Most of what STERIS books each quarter is not a machine. The most optimistic analyst target on STE is $305.00, +19.3% from the $255.76 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for STE?

+

Ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Subsidiary Isomedix agreed to costs of up to roughly ~$48 million to resolve personal injury claims tied to an Illinois sterilization plant, and EtO emissions rules adopted by the EPA in 2024 remain in flux under reconsideration, which cuts both ways: looser rules reduce compliance capex, while continued legal uncertainty has already caused the company to hold off on some capacity expansion. Hospital capital spending is the second pressure point, since sterilizers and surgical tables are deferrable purchases when health systems face margin strain. AST volumes depend on customer manufacturing schedules rather than on STERIS decisions, so device industry destocking passes straight through. The Xodus Medical acquisition adds deal risk: ~$2.1 billion for a business with ~$245 million of revenue is a rich price, the debt it adds raises leverage, and closing depends on regulatory approvals. Tariffs and currency both moved reported results in fiscal 2026 and management flagged them again in the fiscal 2027 outlook. Valuation is itself a risk, because a ~30x trailing multiple leaves little room for a guidance cut, and part of the November guidance raise came from one-off tariff refunds. The most pessimistic published target is $244.00, -4.6% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does STERIS plc do?

+

STERIS makes sterilizers, surgical consumables and cleaning chemistries for hospitals, and runs contract sterilization plants for medical device makers.

What would have to change for STE to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Recurring consumables and service, not equipment sales) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does STERIS actually sell?

+

Three related things. Sterilization and surgical equipment plus the consumables and service contracts that follow it into hospitals, contract sterilization of medical devices at STERIS-owned plants before those devices reach the market, and cleaning chemistries and validation services for pharmaceutical manufacturers. Healthcare is by far the largest of the three at roughly ~70% of revenue, and the pending Xodus Medical deal would add operating room positioning and safety consumables to it.

Is STERIS a US or an Irish company?

+

Both descriptions are partly right. STERIS plc is incorporated in Ireland, which is why the name carries plc, while operations are headquartered in Mentor, Ohio and the majority of revenue is generated in the United States. The shares are ordinary shares listed directly on the NYSE, not an ADR, and STE is an S&P 500 constituent.

When does STERIS report earnings?

+

STERIS runs a fiscal year ending March 31, so its quarters are offset from the calendar. Fiscal 2026 closed on March 31, 2026 and was reported in May 2026 with revenue of roughly ~$5.9 billion. The fiscal 2027 first quarter, covering April through June 2026, was reported on August 6, 2026, the fiscal second quarter (July through September) was reported in early November 2026, and the third quarter is expected around early February 2027.

Walnut is informational, not investment advice, and gives no verdict on STE. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks